Drug Trial Radar · NCT01588171
Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,020
Actual
Start
May 2012
Primary completion
Oct 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Hawler Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 30, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 15 years, up to 48 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.
Conditions
- Venous Thromboembolic Diseases
Interventions
BemiparinDrug
Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
EnoxaparinDrug
Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Venous thromboembolismTime frame: 40 days after delivery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hawler medical university
Erbil, Kurdistan Region, Iraq
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.